<DOC>
	<DOCNO>NCT01655030</DOCNO>
	<brief_summary>The purpose study determine whether creatine monohydrate effective adjuvant treatment bipolar depression .</brief_summary>
	<brief_title>Creatine Monohydrate Adjuvant Therapy Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Individuals eligible study adult age 18 60 year age meet DSMIV criterion assess SCID ( Structural Clinical Interview DSMIV ) type I bipolar disorder , current episode depress . Patients score &gt; 19 MontgomeryAsberg Depression Rating Scale ( MADRS ) include , although two week treatment lithium ( serum level &gt; 0.8 mEq / L ) , valproate ( serum level &gt; 50 mg / L ) quetiapine ( 300600mg/dia dose ) drug combination . Antipsychotics , anticonvulsant , benzodiazepine , thyroid supplementation allow dose remain stable past two week . Antidepressants allow dosage remain stable 4 week . Subjects substance abuse within 2 week inclusion substance dependence 2 month include . Other exclusion criterion : diagnosis schizophrenia , dementia , delirium , epilepsy , mental retardation , clinically unstable medical illness , preexist renal disease , history hypersensibility creatine . Not included individual high risk suicidal homicidal behavior selfmutilation include . Women gestational potential include use reliable contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>